Cancer Clinical Trial 20193161

[LCID Study Number: 20193161]

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

The purpose of this study is to test any good and bad effects of the combination of study drugs called ipilimumab and nivolumab in treating rare cancers and cancers of unknown primary origin.

Disease/Condition: Cancer

Department: Hematology and Oncology

Location(s): Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3421

View NCT ID 02834013 on ClinicalTrials.gov
Protocol #: 20193161
Principal Investigator(s): Corrine Zarwan
Trial Phase: Sponsor Initiated Study Phase 2